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Cardiac cells, like those of the other tissues, undergo regulation through membrane-bound
proteins known as G protein-coupled receptors (GPCRs). β-adrenergic receptors (βARs)
are key GPCRs expressed on cardiomyocytes and their role is crucial in cardiac
physiology since they regulate inotropic and chronotropic responses of the sympathetic
nervous system (SNS). In compromised conditions such as heart failure (HF), chronic
βAR hyperstimulation occurs via SNS activation resulting in receptor dysregulation and
down-regulation and consequently there is a marked reduction of myocardial inotropic
reserve and continued loss of pump function. Data accumulated over the last two decades
indicates that a primary culprit in initiating and maintain βAR dysfunction in the injured and
stressed heart is GPCR kinase 2 (GRK2), which was originally known as βARK1 (for βAR
kinase). GRK2 is up-regulated in the failing heart due to chronic SNS activity and targeting
this kinase has emerged as a novel therapeutic strategy in HF. Indeed, its inhibition or
genetic deletion in several disparate animal models of HF including a pre-clinical pig model
has shown that GRK2 targeting improves functional and morphological parameters of
the failing heart. Moreover, non-βAR properties of GRK2 appear to also contribute to its
pathological effects and thus, its inhibition will likely complement existing therapies such
as βAR blockade. This review will explore recent research regarding GRK2 inhibition; in
particular it will focus on the GRK2 inhibitor peptide known as βARKct, which represents
new hope in the treatment against HF progression.
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INTRODUCTION
Heart failure (HF) is a major and growing public health problem
and despite effective therapy outcomes remain poor with a 5-
year mortality at 50% (Braunwald, 2001; Hunt, 2005). Clinically,
HF is a chronic and severely debilitating syndrome that gener-
ally ends up in a vicious cycle of progressive functional decline
and it is characterized by the insufficient pumping of blood
to meet the needs of the body. During HF, sympathetic ner-
vous system (SNS) activity and levels of catecholamines are
increased in an attempt to drive pump function higher. Initially,
SNS hyperactivity serves to compensate for the reduced cardiac
output, but long-term exposure to high levels of circulating cat-
echolamines causes maladaptive changes to the heart through
dysregulation of their β-adrenergic receptor (βAR) targets and
also causes myocyte death that leads to maladaptive remodeling
of the stressed and failing heart (Woo and Xiao, 2012). Currently,
HF therapy is palliative and protecting the heart against SNS
bombardment through βAR blockers has shown to offer benefit
(Barki-Harrington et al., 2003). However, β-blockers and other
neurohormonal blocking strategies are still not ideal therapies
as not all patients respond favorably to these agents and thus,
new therapeutic strategies are urgently needed. In this regard, a
deeper understanding of the underlying molecular mechanisms
contributing to the development and progression of the disease
represents the best case for future therapeutic advances. In the
last two decades, the study of G protein-coupled receptor (GPCR)
signaling in failing myocardium has led to the identification of
GPCR kinase 2 (GRK2) playing a central role in HF pathology.
Accordingly, the inhibition of GRK2 appears to be a powerful
therapeutic approach and appears to provide complementation
to β-blockade.
βAR IN CARDIAC PHYSIOLOGY AND PATHOLOGY
βARs are the most important GPCR class expressed in the human
heart and represent the most powerful means to increase the
pumping function of the heart. In particular, βARs are the prime
modulators of heart rate and myocardial contractility in response
to catecholamines originating from the SNS (Huang et al., 2011).
Three βAR subtypes (β1, β2, and β3) have been identified in
human cardiac tissue with the β1- and β2ARs representing the
majority of βARs in the myocyte driving functional responses
and these receptors are in a 3–4:1 ratio (β1:β2) in the normal
heart (Frielle et al., 1987; Kobilka et al., 1987; Emorine et al.,
1989). The β3AR is relatively minor although it is present and
may contribute to normal and diseased myocardial regulation
(Aragón et al., 2011). Following catecholamine stimulation, both
β1- and β2ARs couple to adenylyl cyclase (AC) stimulatory G pro-
tein, Gs, leading to cAMP accumulation within the myocyte and
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activation of protein kinase A (PKA). This kinase phosphorylates
many Ca2+ handling protein and some myofilament compo-
nents leading to positive inotropic, lusitropic and chronotropic
effects (Bristow et al., 1990). Importantly, stimulation of cardiac
β2ARs also causes stimulation of pertussis toxin (PTX)-sensitive
Gi signaling pathways (Xiao, 2001). Gi activation can lead to
AC inhibition and also other signaling pathways independent of
β1AR pathways including activation of mitogen-activated protein
kinase (MAPK) pathways and also PI3-kinase and Akt path-
ways (Xiao, 2001). Therefore, these distinct G protein-coupling
characteristics of β1ARs and β2ARs can result in differential regu-
lation and fate of cardiac myocytes (Figure 1). Known differences
include myocyte cell death and survival as β1AR stimulation leads
to apoptosis while β2AR signaling favors cell survival pathways
(Communal et al., 1999; Zaugg et al., 2000). The later has been
shown to be through a β2AR-Gi-Gβγ-PI3K-Akt cell survival sig-
naling pathway and the inhibition of this pathway converts β2AR
signaling from survival to apoptotic (Zhu et al., 2001). β1- and
β2ARs also manifest opposing effects on cardiac cell growth as
stimulation of β1ARs, but not β2ARs, can cause hypertrophy in
cultured neonatal and adult rat cardiac myocytes (Schafer et al.,
2000; Morisco et al., 2001).
GRKs
βARs and other GPCRs undergo regulation for signal termina-
tion immediately following activation through phosphorylation
FIGURE 1 | Differential signaling pathways activated by β1ARs and
β2ARs in cardiomyocytes. Following SNS catecholamines
(Norepinephrine-NE) stimulation, activated β1ARs and β2ARs induce the
production of cAMP through Gs activation of adenylyl cyclase (AC). Next,
cAMP activates PKA resulting in positive chronotropic and inotropic effects.
Secondarily, β1AR through Gs and Calmodulin-dependent kinase (CAMKII)
dependent pathway can induce myocyte apoptotic responses after
increased catecholamine stimulation. In contrast, β2ARs can induce the
activation of Gi dependent cell survival and anti-apoptotic signaling through
Akt. Both β ARs are regulated by GRK2 phosphorylation causing the
dampening of G protein activation and chronically this leads to receptor
down-regulation and the loss of inotropic reserve. Heightened GRK2
activity, as seen in human HF, appears to have a net pro-death effect due, at
least in part to desensitization of β2ARs (Brinks et al., 2010) and also due to
novel GPCR-independent mitochondrial targeting (Chen et al., 2013).
by a family of kinases known as GPCR kinases (GRKs). GRK2 is a
principal GRK involved in intracellular βAR signaling within the
cardiac myocytes (Figure 1) and as discussed below, plays a cru-
cial role in HF (Keys and Koch, 2004). Of the seven mammalian
GRKs that have been identified to date, GRK2 and GRK5 repre-
sent the most abundantly expressed types in the heart and both
can regulate βAR signaling (Huang et al., 2011). In addition to
βARs, GRK2 and other GRKs phosphorylate many receptors and
appear to have some substrate specificity in the heart (Eckhart
et al., 2000). All GRKs are serine/threonine kinases with sim-
ilar structural architecture as they all have a highly-conserved,
central catalytic domain (∼270 aa), flanked by a variable amino-
terminal (NT) domain (∼185 aa) and carboxyl-terminal (CT)
domain (∼105–230 aa) that contains specific regulatory sites
(Rockman et al., 1998b; Vinge et al., 2008). The NT-domain har-
bors several regulatory motifs including a RH domain (regulator
of G protein signaling homology domain) and the CT-domain
mediates the interactions with lipids and membrane proteins
that control the subcellular localization of GRKs (Pitcher et al.,
1998; Penela et al., 2010). Importantly, the CT-domain of GRK2
(and the related GRK3) contains a pleckstrin homology domain
(PH), which interacts with phosphatidylinositol 4,5-biphosphate
(PIP2) and free Gβγ subunits. Following these interactions, GRK2
translocates to the plasmamembrane enhancing activated GPCRs
phosphorylation. GRK5 does not have this domain and does not
use Gβγ to target the plasma membrane and thus, GRK2 can be
selectively targeted through CT-derived peptides that keep GRK2
off the membrane and can limit the desensitization of GPCRs
including cardiac βARs (Koch et al., 1993, 1995).
GRK2 AND βAR SIGNALING IN HF
As mentioned above, GRKs phosphorylate activated recep-
tors leading to desensitization to control their over-stimulation
(Freedman et al., 1995; Rockman et al., 2002) and since βARs are
an important part of the heart’s response toward stress and injury
they are GRK targets. Following GRK-mediated phosphorylation
of βARs in the heart, β-arrestins are recruited to these receptors
and these adaptor molecules block further G protein activation
(Ferguson, 2001). β-arrestins then internalize receptors leading
to their degradation, resensitization and return to the membrane
or induce G protein-independent signaling (Pitcher et al., 1998).
Overall, βAR signaling is critical for both normal and diseased
heart function and as introduced above their dysregulation in
injured/stressed myocardium is a cardinal characteristic of HF.
Over the last two decades GRK2 has been shown to be the central
culprit in cardiac βAR dysregulation as its up-regulation causes a
loss of βAR responsiveness that is marked by both chronic recep-
tor desensitization and down-regulation, which originally occurs
due to heightened SNS activity (Bristow et al., 1982; Iaccarino
et al., 1998; Rengo et al., 2009; Raake et al., 2013). Importantly, the
major βAR down-regulation that occurs is selective for the β1AR
and this causes a change in β1:β2 ratio to closer to equal (Bristow
et al., 1990; Rockman et al., 1998a; White et al., 2000). Certainly,
the up-regulation of GRK2 (and also probably GRK5) caused by
SNS activation acts as a “brake” for cardiac βAR signaling and this
is a partial reason why β-blockers have some beneficial effects in
HF as they can block the noxious effects of catecholamines on the
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cardiac myocyte. However, increased GRK2 activity has proven to
be maladaptive in HF and its inhibition has emerged as a thera-
peutic target (Lymperopoulos et al., 2012). Interestingly, chronic
β-blocker use has shown including in HF models, to decrease
GRK2 expression levels, which from data with GRK2 lowering
alone, could contribute to their therapeutic effects (Iaccarino
et al., 1998; Rengo et al., 2009).
YIN AND YANG OF HF THERAPY-BETA ADRENERGIC RECEPTORS
BLOCKERS
β-blockers are currently considered as the mainstay of HF ther-
apy. Behind pharmacologic β-blockade action is the ability of
these molecules to inhibit the excessive catecholamine stim-
ulation of inotropic βARs that induce myocyte cell death so
resulting in cardiac deterioration, and changes in ventricular
mass and that promote ventricular dilation through HF (Mann,
1999; Bristow, 2011). Importantly, although β-blockers only indi-
rectly address key molecular signaling alterations within the
cardiac myocyte, their clinical use substantially improves HF
prognosis increasing survival rate of HF patients and reduc-
ing re-hospitalization (Bristow, 1997, 2000). Interestingly, it has
been observed that at molecular level, sustained therapy with
β-blockers in HF is associated with resensitization of βARs, nor-
malization of GRK2 levels and activity and as a consequence,
β-blockers cause the upregulation of cardiac βARs (down-
regulated in HF) increasing βAR signaling when they are activated
(Leineweber et al., 2005). However, the full extent of whether
these molecular changes are the true therapeutic mechanisms
of action of βAR antagonists in HF is not fully understood as
there are some specific differences in β-blockers classes used.
In fact, β-blockers are a heterogeneous group of pharmaco-
logic agents with a number of different actions that include
β1AR and β2AR antagonism, intrinsic sympathomimetic activ-
ity (ISA) (Jaillon, 1990), inverse agonism (Chidiac et al., 1994)
and guanine nucleotide binding regulation (Bristow et al., 1992).
Further, β-blockers may possess additional properties such as
vasodilatation via α1AR antagonism and non-adrenergic phar-
macological properties such as quinidine-like (or “membrane
stabilizing”) effects in model systems (Tritthart et al., 1969) and
may have also significant antioxidant properties (Dandona et al.,
2000).
Of note, β-blocker therapy has limitations in the HF patient
population and it is not tolerated by all patients and is certainly
not an ideal therapeutic. For example, long-term treatment with
β-blockers in HF patients is associated with risk of unwanted
systemic side effects. In this context it has been described that
increased bradycardia (due to depression of the cardiac conduc-
tion system), hypotension, dizziness, weakness, and worsening
of depression represent some of the major deleterious effects of
β-blocker non-selectivity (Packer, 2001). Furthermore, dose, a
critical factor for therapeutic success, has to be titrated individ-
ually for each HF patient. Finally, not all HF patients are suited
for β-blocker treatment, opening a demand for new therapeu-
tic strategies. For this reason the development of new potential
molecules that minimize the unfavorable effects and potentially
allow dose reduction is absolutely needed and we believe inhibit-
ing GRK2 is an attractive target not only because it can also
normalize βAR signaling but also it appears to have exciting
and novel non-GPCR effects that has appeal for targeting its
inhibition that can synergize with β-blocker use in HF patients
(see below).
GRK2 NON-RECEPTOR FUNCTIONS IN HF
Although as discussed above it is clear that enhanced activ-
ity of GRK2 in HF negatively affect βAR signaling, we have
recently demonstrated that GRK2 can induce myocardial pathol-
ogy through other systems including non-GPCR activity that can
negatively affect myocyte metabolism and cell survival (Brinks
et al., 2010; Ciccarelli et al., 2011; Chen et al., 2013; Fan et al.,
2013). For example, data now supports GRK2 being a molecular
link between the excessive neurohormonal activation that follows
cardiac stress and initiation of defects in myocyte energy sub-
strate use by negatively affecting glucose uptake in the myocyte
through insulin-dependent phosphorylation of insulin recep-
tor substrate-1 (IRS1) that causes a loss of signaling (Ciccarelli
et al., 2011). Thus, GRK2 appears to directly modulate signal-
ing through this non-GPCR and participates in the physiological
regulation of myocardium insulin signaling. Moreover, our group
have also showed that elevated levels of GRK2 in cardiomyocytes
cause excessive cell death after acute ischemic injury and tar-
geted inhibition or genetic deletion significantly protects the heart
(Brinks et al., 2010; Fan et al., 2013), which importantly argues
against GRK2-up-regulation being initially adaptive as elevated
GRK2 activity appears to be maladaptive at all times prior to
and after cardiac stress. The pro-death effects of GRK2 may be
β2AR dependent (Brinks et al., 2010) or non-GPCR dependent
as we have found that myocyte death during ischemic stress can
be regulated by GRK2 levels found within mitochondria as GRK2
is associated with increased mitochondrial-dependent pro-death
signaling and also caused increased Ca2+-induced opening of the
mitochondrial permeability transition pore, a key step in cellular
injury (Chen et al., 2013). Accordingly, GRK2 inhibition reduces
IRS1-phosphorylation improving insulin signaling and as a result
increase glucose uptake in the ischemic cardiomyocytes and its
inhibition but also reduces the pro-apoptotic pathway activated
by this kinase in response to ischemia. For these reasons it is
important to underline that these non-classical roles of GRK2
strongly support the idea that developing a therapy that selec-
tively inhibits GRK2 could synergize and increase the efficacy of
β-blockers as GRK2 inhibition would result in additional benefits
independent of βARs. In fact, several animal studies have shown
significant HF benefit when GRK2 is lowered or inhibited con-
current with βAR antagonists (Harding et al., 2001; Raake et al.,
2008; Rengo et al., 2009).
GRK2 INHIBITION AS A POTENTIAL APPROACH FOR HF TREATMENT
Over the last two decades, our lab and others have shown that
lowering GRK2 expression or activity in the injured, stressed or
failing heart can prevent or reverse ventricular dysfunction at the
functional and morphological level (Huang et al., 2011). This has
been shown using a CT-derived peptide inhibitor known as the
βARKct and also in GRK2 knockout (KO) mice. First, cardiac-
specific βARKct transgenic mice were created showing increased
inotropic reserve (Koch et al., 1993) and these mice have been
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used to prevent HF in several genetic mouse models (Rockman
et al., 1998a; Freeman et al., 2001; Harding et al., 2001). In addi-
tion, viral-mediated βARKct delivery to rats, rabbits, and pigs
have shown significant beneficial effects including improved car-
diac function and reverse ventricular remodeling (White et al.,
2000; Shah et al., 2001; Tevaearai et al., 2001; Rengo et al., 2009;
Raake et al., 2013). Similar HF rescue by induced KO of GRK2 in
mice after HF was evident is consistent with βARKct-mediated
activity being GRK2 inhibition (Raake et al., 2008). Although
there are some minor differences between GRK2 inhibition with
βARKct and GRK2 KO (Matkovich et al., 2006; Raake et al., 2008;
Völkers et al., 2011) the data is overwhelming in supporting GRK2
targeting as beneficial in the failing heart.
Importantly, a recent pre-clinical, large animal HF study has
been done that demonstrates the clinical potential of βARKct-
mediated gene therapy (Raake et al., 2013). This study used
adeno-associated virus serotype-6 (AAV6) to deliver βARKct to
a post-ischemic HF model in the pig (Pleger et al., 2011; Raake
et al., 2013). We found that AAV6-βARKct delivery via retro-
grade coronary venous perfusion ameliorated LV function, and
suppressed adverse cardiac remodeling and fetal gene expres-
sion in this model (Raake et al., 2013). Of note, this pig study
recapitulated similar results found with AAV6-βARKct delivery
to a rat model of HF where it was also shown that βARKct
worked significantly better that β-blockade alone and the two
were complementary together (Rengo et al., 2009). Of impor-
tance, both of these studies showed that chronic GRK2 inhibition
results in significant lowering of catecholamines and aldosterone
demonstrating feedback to decrease the neurohormonal outflow
associated with negative prognosis in HF (Rengo et al., 2009;
Raake et al., 2013). These two studies in particular are impor-
tant as they show reversal of the disease process and the pig study
closely reflect human pathophysiology and is a pre-requisite for
future clinical trials.
EMERGING SMALL MOLECULE INHIBITORS OF GRK2
Gene therapy for HF is now becoming a reality (Jaski et al., 2009;
Jessup et al., 2011) and AAV6-βARKct trials are in the plan-
ning stages, GRK2 inhibition by small pharmacological agents
would offer many advantages to the HF patient. Interestingly,
several recent molecules have been developed and described that
have GRK2 inhibitory properties. Two decades ago, heparin and
related compounds were shown to block GRK2 activity how-
ever, the direct access to GRK2, the high concentration and the
intrinsic cytotoxicity made them not useful for either in cell-
based assays or in in vivo scenarios (Lohse et al., 1989; Kim et al.,
1993; Hasbi et al., 2000; Kassack et al., 2000; Winstel et al., 2005).
RNA molecules such as aptamers have been also investigated as a
new approach to efficiently block GRK2 activity and the RNA-
aptamer C13, was shown to be able to bind to GRK2 with a
high affinity and inhibit GRK2-catalyzed rhodopsin phospho-
rylation (Mayer et al., 2008). All the studies that have analyzed
the efficacy of C13, suggest that this RNA-aptamer might repre-
sent a starting point for the development of small molecules that
specifically target GRK2. Unfortunately, this molecule has been
tested only in in vitro models and no in vivo study at this time is
present.
Interestingly, molecules have recently emerged that target the
GRK2-Gβγ protein-protein interaction and thus, have mecha-
nisms identical to the βARKct. M119 is such a molecule (Bonacci
et al., 2006; Casey et al., 2010) and it has been shown to work
in vitro and in vivo on cardiac cells and in the heart preventing
ventricular dysfunction after chronic catecholamine exposure and
also showing positive results similar to the βARKct in a genetic
model of cardiomyopathy (Casey et al., 2010). Gallein is a related
molecule that blocks GRK2-Gβγ and it has also shown positive
results in vivo (Piao et al., 2012). These are promising results,
however, these compounds are not true pharmacological agents
in a “drugable” sense and have severe limitations that preclude
human use (Casey et al., 2010).
Recently, we have found that an existing FDA-approved drug
has significant GRK2 inhibitory properties and potentially this
off-target effect may be seen in humans. The serotonin reup-
take inhibitor (SSRI), paroxetine has affinity for GRK2 and
has significant GRK2 inhibitory properties in vitro and in vivo
(Thal et al., 2012). Paroxetine binds in the active site of GRK2
and stabilizes the kinase domain in a novel conformation in
which a unique regulatory loop forms part of the ligand bind-
ing site (Thal et al., 2012). Further, this drug causes increased
isoproterenol-induced shortening and contraction amplitude in
cardiomyocytes in vitro, and pretreatment in vivo of mice with
paroxetine before isoproterenol significantly increases left ven-
tricular inotropic reserve with no significant effect on heart
rate (Thal et al., 2012). This agent used for clinical depres-
sion probably is not viable for use as a specific GRK2 inhibitor
but is a great starting point for chemistry to develop novel
GRK2 inhibitors that can be used eventually for cardiovascular
disorders.
CONCLUSIONS AND FUTURE PERSPECTIVES
As demonstrated by us and others, targeted GRK2 inhibition pri-
marily by βARKct expression and some emerging small molecules
have shown sustained improvement of global cardiac function
and reversal of LV remodeling at least in part due to the normal-
ization of the neurohormonal signaling axis and βAR signaling.
In addition, non-GPCR effects of lowering GRK2 activity, has
positive effects on cardiac metabolism and on cell survival/death
pathways (Figure 2). Importantly, the specific targeting of GRK2
appears similar whether there is inhibition by βARKct or delet-
ing gene expression. Therefore, taken together, these results
strongly suggest that the inhibition/lowering of GRK2 activity
is a valid and promising novel molecular approach for treat-
ing HF. Most studies, including studies with βARKct expres-
sion in HF pigs, have shown a reversal of βAR dysfunction
including receptor upregulation and a normalization of signal-
ing; however, no doubt, there are effects of the βARKct that
go beyond resensitization of cardiac βARs and these effects are
currently being explored by us and others. Therefore, these
results have launched a clinical gene therapy approach using
the βARKct with a Phase I clinical trial being actively planned
in order to obtain the best cardio-selective HF treatment that,
as widely proven by all gathered data collected by us, could
be used alone or in conjunction with the actual β-blockers
therapy.
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FIGURE 2 | Multiple protective role of βARKct in failing
myocardium against high GRK2 levels. Schematic representation
of GRK2-inhibition mediated by βARKct: (1) βARKct, like GRK2, binds
to Gβγ subunits after GPCR (e.g., βARs) activation and reduces the
capability of GRK2 to induce dysregulation/downregulation of these
receptors; (2) βARKct antagonizes GRK2 dependent phosphorylation
of IRS1 increasing glucose uptake in myocytes; (3) βARKct blocks
the ischemia-induced mitochondria localization of GRK2 through
inhibition of MAPK-dependent Hsp90 binding, inhibiting pro-apoptotic
signaling.
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